

Remote Oxidation of Aliphatic C–H Bonds in Nitrogen-Containing Molecules

Jennifer M. Howell,[‡] Kaibo Feng,[‡] Joseph R. Clark, Louis J. Trzepkowski, and M. Christina White*[‡]

Roger Adams Laboratory, Department of Chemistry, University of Illinois, Urbana, Illinois 61801, United States

S Supporting Information

ABSTRACT: Nitrogen heterocycles are ubiquitous in natural products and pharmaceuticals. Herein, we disclose a nitrogen complexation strategy that employs a strong Brønsted acid (HBF₄) or an azaphilic Lewis acid (BF₃) to enable remote, non-directed C(sp³)–H oxidations of tertiary, secondary, and primary amine- and pyridine-containing molecules with tunable iron catalysts. Imides resist oxidation and promote remote functionalization.




Figure 1. Heterocycle functionalization.

The development of reactions that selectively oxidize inert C(sp³)–H bonds while tolerating more electron-rich nitrogen functionality is a significant unsolved problem, given that nitrogen is ubiquitous in natural products and medicinal agents.¹ Among the challenges for developing such reactions are catalyst deactivation via nitrogen binding and direct oxidation of nitrogen to furnish N-oxides. Common electronic deactivation strategies for secondary (2°) and primary (1°) amines (e.g., acylation) do not disable hyperconjugative activation leading to functionalization α to the nitrogen (Figure 1).² Directing group strategies facilitate oxidation of C(sp³)–H bonds that are spatially and geometrically accessible from the directing functional group.³ Remote oxidation of C(sp³)–H bonds in nitrogen-containing molecules is not currently possible with ligated transition metal catalysis.

Site-selective and -divergent oxidation of tertiary (3°) and 2° C–H bonds has been demonstrated with small molecule catalysts, Fe(PDP) **1** and Fe(CF₃PDP) **2**, respectively.⁴ Discrimination of C–H bonds can be accomplished via catalyst/substrate electronic, steric, and stereoelectronic interactions. Inductive effects within a substrate strongly influence site-selectivity, as highly electrophilic metal oxidants (e.g., Fe=O) disfavor oxidation of electron-deficient C(sp³)–H bonds. Functionalities with positive charges, such as ammonium cations, or strongly polarized dative bonds, such as amine–borane adducts, exert a strong inductive effect on adjacent C–H bonds.⁵ We hypothesized that Lewis/Brønsted acid complexation of nitrogen would afford nitrogen tolerance and remote site-selectivity in iron-catalyzed C(sp³)–H oxidations. Herein, we describe strategies that enable remote, non-directed aliphatic C–H oxidation in substrates containing prevalent nitrogen functional groups: amines (3°, 2°, 1°) and pyridines. Imides tolerate oxidative conditions without complexation and promote remote C(sp³)–H oxidation.

We evaluated two strategies to effect nitrogen tolerance/remote oxidation: azaphilic, oxidatively stable Lewis acid complexation with boron trifluoride (BF₃), and irreversible

protonation with tetrafluoroboric acid (HBF₄), a strong Brønsted acid with a weakly coordinating counterion. Whereas some precedent exists with these strategies for C–H oxidations,⁶ olefin oxidations,^{7a,b} and metathesis,^{7c} no examples of remote aliphatic C–H oxidations under ligated transition metal catalysis are known. In metal complexes having basic, dative ligands (e.g., PDP), competitive complexation with acid may lead to catalyst deactivation. Exploration of BF₃ complexation with both 3° piperidine **3a** and pyridine **4a** provided encouraging yields of remotely oxidized products (Table 1, entries 1, 2). HBF₄ protonation afforded remote oxidation products with improved yields for both **3a** and **4a** (entries 3, 7). The same protocol with trifluoroacetic acid or sulfuric acid,^{6c} which generate more coordinating counterions, was not effective (entries 4, 5). An in situ HBF₄ protocol resulted in diminished yield of **5a**, suggesting excess acid is not beneficial (entry 6). Oxidation of pyridine N-oxide **4b** was unproductive (entry 8).^{6a}

Oxidation of acyl-protected piperidines (**3b,c**, entries 9, 10) resulted in over-oxidized products, likely via N-dealkylation pathways. Both HBF₄ protonation and BF₃ complexation are effective with 2° piperidine **3d** (entries 11, 12). The BF₃ complexation strategy is preferable for 2° and 1° amines due to facile purification of oxidized amine–BF₃ complexes. Additionally, these complexes can be stored without precaution to exclude atmosphere.⁸ Despite indiscriminate oxidation of carbamates and amides, we found that imides attenuate nitrogen basicity and enable remote oxidation (entry 13).

Remote methylene oxidation of piperidine **3g** and pyridine **4c** with Fe(CF₃PDP)^{4c} afforded good overall yields but with significantly diminished site-selectivities (entries 14, 15). In contrast, Fe(PDP) hydroxylation of remote 3° C–H bonds proceeds with high site-selectivity; no benzylic or methylene oxidation products were detected. HBF₄ protonation/oxidation

Received: October 1, 2015


Published: November 4, 2015

Table 1. Reaction Optimization^{a,b}

Entry	Heterocycle	R ₁	R ₂	Additive (equiv)	Yield (%) (rsm) ^e
1	3a	Me	-	BF ₃ •OEt ₂ (1.1)	46 (28)
2	4a	-	-	BF ₃ •OEt ₂ (1.1)	27 (67)
3	3a	Me	-	HBF ₄ •OEt ₂ (1.1)	56 (29)
4	3a	Me	-	F ₃ CCO ₂ H (1.1)	5 (74)
5 ^f	3a	Me	-	H ₂ SO ₄ (1.1)	0 (76)
6 ^g	3a	Me	-	HBF ₄ •H ₂ O (1.1)	43 (40)
7	4a	-	-	HBF ₄ •OEt ₂ (1.1)	57 (23)
8 ^a	4b	O	-	-	0 (65)
9 ^a	3b	Boc	-	-	n.d. (37)
10 ^a	3c	TFA	-	-	n.d. (11)
11	3d	H	-	HBF ₄ •OEt ₂ (1.1)	40 (26)
12 ^{a,h}	3e	H	BF ₃	-	44 (22)
13 ^a	glutarimide 3f	-	-	Fe(PDP) 1 ^c	70 (8)
14	3g	Me	-	HBF ₄ •OEt ₂	57 (4)
15	4c	-	-	Fe(CF ₃ PDP) 2 ^c	53 (10)

^aIterative addition (3X): 5 mol% **1**, AcOH (0.5 equiv), H₂O₂ (1.2 equiv), MeCN.^{4a} ^bSlow addition: 25 mol% **2**, AcOH (5.0 equiv), H₂O₂ (9.0 equiv), MeCN, syringe pump 6 mL/min.^{4b,c} ^cCatalyst enantiomers used interchangeably. ^dMethod A: (i) additive (1.1 equiv), CH₂Cl₂, concentrated in vacuo, (ii) iterative addition, (iii) 1 M NaOH. ^eIsolated yields, % recovered starting material (rsm). ^fNo product observed with H₂SO₄ (0.55 equiv). ^gIn situ addition of HBF₄ (1.1 equiv). ^h2° piperidine-BF₃ complex **3e** isolated and purified. Product **5e** isolated/purified as 2° piperidine-BF₃ complex. ⁱMethod B: (i) HBF₄•OEt₂ (1.1 equiv), CH₂Cl₂, concentrated in vacuo, (ii) slow addition, (iii) 1 M NaOH. ^jBased on isolation.

of a linear substrate with competing 3° sites proceeded with excellent selectivity (>20:1 distal/proximal), favoring the site distal from the protonated amine (eq 1). Electron-withdrawing



groups (e.g., Br, F, OAc) previously evaluated did not afford such strong inductive deactivation of proximal sites (9:1, 6:1, 5:1 distal/proximal, respectively).^{4a} Collectively, these data suggest that Brønsted/Lewis acid complexation renders basic nitrogen a strong inductive withdrawing moiety, enabling remote C-H oxidations often with high site-selectivities.

Piperidines substituted at N, C4, and C2 are the most prevalent nitrogen heterocycles in drugs.^{1a} Employing HBF₄ protonation, Fe(PDP)-catalyzed tertiary oxidations of *N*-methyl-

Table 2. Basic Amines^a


Entry	Substrate	Yield (%) (rsm)
10a	10a	52% (28%)
10b	10b	55% (20%)
10c	10c	58% (32%)
10d	10d	50% (41%)
10e	10e	40% (25%) ^{d,e}
10f	10f	50% (24%) ^d 46% (28%) ^f with Fe(PDP)
10g	10g	54% (10%)
10h	10h	60% (21%)
10i	10i	56% (26%) ^c with HBF ₄ 43% (22%) ^h with BF ₃
10j	10j	65% (31%)
10k	10k	trace (74%)
10l	10l	54% (7%) ⁱ
10m	10m	47% (11%) ^d with HBF ₄
10n	10n	56% (22%)

^aIsolated yield is average of two runs, % rsm in parentheses. ^bCatalyst enantiomers used interchangeably. ^cMethod A with HBF₄•Et₂O (1.1 equiv). ^dMethod B. ^eStarting material recycled 1X. ^fMethod B with 1. ^gMethod A with BF₃•Et₂O (1.1 equiv), concentrated and purified prior to use. Isolated as BF₃ complex, no NaOH workup. ^hMethod A with BF₃•Et₂O (1.1 equiv). ⁱMethod B with BF₃•Et₂O (1.1 equiv), concentrated and purified prior to use. Isolated as BF₃ complex, no NaOH workup.

or *N*-alkyl-substituted piperidines proceeded uniformly in high yields and with excellent site-selectivities to afford 3° hydroxylated products (Table 2). Notably, piperidine **9a** with C2-alkyl substitution was hydroxylated in 52% yield (**10a**), showcasing the effectiveness of HBF₄ protonation in sterically hindered environments. Piperidines with a variety of functional groups (esters, nitriles, electron-deficient aromatics) perform well under conditions where competitive hydrolysis or oxidation may occur (**10b–f**). The 4-phenylpiperidine motif in **10d,e** represents a pharmacophore found in opioids such as ketobemidone and haloperidol.⁹ Improved site-selectivities for Fe(CF₃PDP)-catalyzed remote methylene oxidations were observed in substrates having more electronically differentiating elements (**10e,f** 40% and 50%, respectively).


Analogous 2° piperidine-BF₃ complexes worked with equal facility for remote tertiary and secondary oxidations (Table 2). Underscoring the variance in electronics between 3° and 2° C-H bonds, oxidation of **9j** delivered 3° alcohol **10j** in 65% yield, whereas methylene oxidation of **9k** gave trace product. The BF₃ complexation strategy is preferred for oxidation of sterically unencumbered 2° and 1° amines (**10n**), where challenges in product isolation with HBF₄ protonation lead to diminished isolated yields (**10l** vs **10m**). Protonation with HBF₄ is advantageous in cases where steric hindrance at nitrogen retards effective BF₃ coordination (**10i** 56% and 43% yield, respectively). Hydroxylated amine-BF₃ complexes are readily converted to the

Scheme 1. Amine Deprotection Strategies



free amine via base-mediated hydrolysis or exposure to a nucleophilic fluoride source (Scheme 1). The latter protocol is advantageous for substrates containing hydrolytically unstable functional groups, such as **10g**.


Pyridines are the most prevalent heteroaromatic in FDA-approved pharmaceuticals.^{1a} Fe(PDP)-catalyzed remote hydroxylation of 3° sites in 2-alkylpyridines proceeded smoothly using HBF₄ protonation for both mono- and disubstituted substrates (**13a** 59%, **13b** 61%, Table 3). In these sterically encumbered substrates, complexation with BF₃ affords diminished yields (32% and 34%, respectively). Long-chain 3-alkylpyridines, prevalent in natural products,¹⁰ are efficiently oxidized (**13c** 50%). Remote oxidation proceeds in good yields

Table 3. Pyridines^a

^aIsolated yield is average of two runs, % rsm in parentheses. ^bCatalyst enantiomers used interchangeably. ^cMethod A with HBF₄·Et₂O (1.1 equiv). ^dMethod B with BF₃·OEt₂ (1.1 equiv), catalyst **1**, and 20% NaOH workup. ^e(+)-**13f** refers to pure alcohol. ^fStarting material recycled 1×. ^gBased on isolation. ^hMethod B. ⁱ1.6:1 C3/C4 adjusted for number of hydrogens.

with electron-rich pyridines (**6a**, **13d**), whereas yield and mass balance are lower with an electron-deficient substrate (**13e** 34% yield, 29% recovered starting material (rsm)). Pyridines having less electronically favored and exposed 3° sites afford modest site-selectivity (**13f** 52%, 2.7:1). The one carbon shortened analogue of 4-pentylpyridine (**4c**, Table 1) underwent methylene oxidation with improved site-selectivity (>20:1) but in diminished yield (**13g** 32% yield). In cyclohexanes^{4b} having bulky, inductive withdrawing substituents, stereoelectronic preference for oxidation at C3 overrides electronic preference for oxidation at C4 (**13h** 1.6:1 C3/C4 adjusted for number of hydrogens).

Imides are abundant in biologically active molecules and serve as synthetic precursors to amines.¹¹ Succinimide **14a** and glutarimide **14b** were oxidized in excellent yield, without requirement for Brønsted/Lewis acid complexation, to afford

Table 4. Imides^{a,b}


^aIsolated yield is average of two runs, % rsm in parentheses. ^bIterative addition. ^cCatalyst enantiomers used interchangeably. ^dStarting material recycled 1×.

the corresponding alcohols (Table 4). Cyclopropyl-modified succinimides are tolerated in this C–H oxidation reaction (**15c,d**). Spirocyclic glutarimide **14f**, a substructure in anxiolytic agent buspirone,¹² underwent site-selective methylene oxidation in good yield (57%). Analogous to reactivity in enzymatic oxidations,^{1b} we have observed Fe(PDP) to effect both oxidative *N*-dealkylation of amines and oxidation of electron-neutral or -rich aromatics. No *N*-demethylation was observed with imide **14e** (57%), and both 4-nitrothalimide **14g** and unsubstituted phthalimide **14h** were oxidized in useful yields (**15g** 58%, **15h** 46%).¹³ Underscoring the medicinal relevance of this reaction, oxidation of thalidomide analogue **14i** afforded **15i** in good yield (54%). Imides are oxidatively stable and inductively deactivating motifs that promote remote oxidations.

We evaluated the efficacy of the aforementioned nitrogen protection strategies paired with Fe(PDP) or Fe(CF₃PDP) oxidation in the late-stage diversification of medically important complex molecules. Dextromethorphan, an antitussive drug of the morphinan class, contains a basic *N*-methylpiperidine moiety, an aromatic ring, and a benzylic site, all highly prone to oxidation (Scheme 2A). We hypothesized that benzylic deactivation would result from the proximally fused tertiary piperidine, which as its ammonium BF₄ salt would be rendered a strong inductive withdrawing group. Exposure of **16** to HBF₄ protonation/Fe((*S,S*)-CF₃PDP) oxidation afforded remote, non-benzylic oxidation products, ketone **17** and diastereomerically pure alcohol **18** in 45% yield with preference for the least sterically hindered methylene site (2.5:1 ketone/alcohol).

Abiraterone acetate, having a C17-(3-pyridyl) motif, is a steroidal antiandrogen used in the treatment of prostate cancer. Despite a strong preference for oxidation at 3° benzylic sites (BDE ≈ 83 kcal/mol),¹⁴ exposure of **19** to HBF₄ protonation/Fe((*R,R*)-CF₃PDP) oxidation resulted in a site-selective and diastereoselective remote oxidation at C6 (BDE ≈ 98 kcal/mol) of the steroid core in 42% yield (6:1 alcohol/ketone) (Scheme 2B). These represent the first examples of transition metal catalyzed remote, aliphatic C–H oxidations on a morphinan and nitrogen-containing steroid skeletons.

Cycloheximide, a readily available natural product with broad antimicrobial activity but high toxicity, is currently used as a protein synthesis inhibitor. The C4 hydroxylated analogue, streptovitacin A **22**, has shown diminished toxicity and has been obtained via an eight-step de novo synthesis proceeding in 7%

Scheme 2. Late-Stage Functionalization of Nitrogen-Containing Molecules^a

^aIsolated yield is average of two runs. ^bSubstrates containing chirality demonstrated matched/mismatched reactivity with catalyst enantiomers. ^c(i) HBF₄·Et₂O (1.1 equiv), CH₂Cl₂, concentrated in vacuo, (ii) slow addition with 2, (iii) 1 M NaOH. ^dBased on isolation. ^e(+)-20 refers to pure alcohol. ^f(i) HBF₄·Et₂O (1.1 equiv), CH₂Cl₂, concentrated in vacuo, (ii) iterative addition with 2, (iii) NaHCO₃. ^gStarting material recycled 2X. ^hIterative addition with 1.

overall yield.¹⁵ The direct oxidation of cycloheximide derivative 21 with Fe((S,S)-PDP) affords streptovitamin A derivative 23 in one step and in excellent yield (50%) (Scheme 2C), underscoring the power of remote late-stage C–H oxidation to streamline synthesis.

We have demonstrated remote Fe(PDP)-catalyzed oxidation in a range of nitrogen heterocycles by employing Brønsted/Lewis acid complexation strategies. We envision this will be a highly enabling methodology for the generation of medicinal agents via late-stage oxidation and for the evaluation of their metabolites.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.5b10299.

Experimental details and characterization data (PDF)

Spectral data (PDF)

X-ray crystallographic data for 20-ketone (CIF)

■ AUTHOR INFORMATION

Corresponding Author

*mcwhite7@illinois.edu

Author Contributions

‡J.M.H. and K.F. contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support was provided by the NIH/NIGMS (GM 112492). We thank G. Snapper for initial investigations, J. Griffin, J. Zhao, and T. Osberger for spectra inspection, C. Delaney for checking procedures, Dr. L. Zhu for assistance with NMR data analysis, and Dr. J. Bertke and Dr. D. Gray for crystallographic data and analysis. We thank Zoetis for an unrestricted grant to explore C–H oxidations in pharmaceuticals.

■ REFERENCES

(1) (a) Vitaku, E.; Smith, D. T.; Njardarson, J. T. *J. Med. Chem.* **2014**, *57*, 10257. (b) White, M. C. *Science* **2012**, *335*, 807. (c) Nam, W.; Lee, Y.-M.; Fukuzumi, S. *Acc. Chem. Res.* **2014**, *47*, 1146.

(2) (a) Campos, K. R. *Chem. Soc. Rev.* **2007**, *36*, 1069. (b) Catino, A. J.; Nichols, J. M.; Nettles, B. J.; Doyle, M. P. *J. Am. Chem. Soc.* **2006**, *128*, 5648. (c) Condie, A. G.; González-Gómez, J. C.; Stephenson, C. R. J. *J. Am. Chem. Soc.* **2010**, *132*, 1464. (d) Hari, D. P.; König, B. *Org. Lett.* **2011**, *13*, 3852. (e) Noble, A.; MacMillan, D. W. C. *J. Am. Chem. Soc.* **2014**, *136*, 11602. (f) He, J.; Hamann, L. G.; Davies, H. M. L.; Beckwith, R. E. *J. Nat. Commun.* **2015**, *6*, 5943.

(3) (a) McNally, A.; Haffemayer, B.; Collins, B. S. L.; Gaunt, M. J. *Nature* **2014**, *510*, 129. (b) Chan, K. S. L.; Wasa, M.; Chu, L.; Laforteza, B. N.; Miura, M.; Yu, J.-Q. *Nat. Chem.* **2014**, *6*, 146.

(4) (a) Chen, M. S.; White, M. C. *Science* **2007**, *318*, 783. (b) Chen, M. S.; White, M. C. *Science* **2010**, *327*, 566. (c) Gormisky, P. E.; White, M. C. *J. Am. Chem. Soc.* **2013**, *135*, 14052.

(5) (a) Anslyn, E. V.; Dougherty, D. A. *Modern Physical Organic Chemistry*; University Science Books: Sausalito, CA, 2006; pp 15–16. (b) Staubitz, A.; Robertson, A. P. M.; Sloan, M. E.; Manners, I. *Chem. Rev.* **2010**, *110*, 4023.

(6) Pyridines in Pd(II)/sulfoxide allylic C–H oxidation: (a) Malik, H. A.; Taylor, B. L. H.; Kerrigan, J. R.; Grob, J. E.; Houk, K. N.; Du Bois, J.; Hamann, L. G.; Patterson, A. W. *Chem. Sci.* **2014**, *5*, 2352. Aliphatic amines with methyl(trifluoromethyl) dioxirane (TFDO): (b) Asensio, G.; González-Núñez, M. E.; Bernardini, C. B.; Mello, R.; Adam, W. *J. Am. Chem. Soc.* **1993**, *115*, 7250. Shilov oxidation of aliphatic amines (5 equiv): (c) Lee, M.; Sanford, M. S. *J. Am. Chem. Soc.* **2015**, *137*, 12796.

(7) (a) Ferrer, M.; Sánchez-Baeza, F.; Messeguer, A.; Diez, A.; Rubiralta, M. *J. Chem. Soc., Chem. Commun.* **1995**, 293. (b) Brennan, M. B.; Claridge, T. D. W.; Compton, R. G.; Davies, S. G.; Fletcher, A. M.; Henstridge, M. C.; Hewings, D. S.; Kurosawa, W.; Lee, J. A.; Roberts, P. M.; Schoonen, A. K.; Thomson, J. E. *J. Org. Chem.* **2012**, *77*, 7241. (c) Woodward, C. P.; Spiccia, N. D.; Jackson, W. R.; Robinson, A. J. *Chem. Commun.* **2011**, 47, 779.

(8) Hampe, E. M.; Rudkevich, D. M. *Tetrahedron* **2003**, *59*, 9619.

(9) Zimmerman, D. M.; Nickander, R.; Horng, J. S.; Wong, D. T. *Nature* **1978**, *275*, 332.

(10) O'Hagan, D. *Nat. Prod. Rep.* **1997**, *14*, 637.

(11) Gören, M. Z.; Onat, F. *CNS Drug Rev.* **2007**, *13*, 224.

(12) Wu, Y.-H.; Rayburn, J. W.; Allen, L. E.; Ferguson, H. C.; Kissel, J. W. *J. Med. Chem.* **1972**, *15*, 477.

(13) Schmidt, V. A.; Quinn, R. K.; Brusoe, A. T.; Alexanian, E. J. *J. Am. Chem. Soc.* **2014**, *136*, 14389.

(14) Luo, Y.-R.; Cheng, J.-P. In *CRC Handbook of Chemistry & Physics*, 94th ed.; Haynes, W. M., Ed.; CRC Press: Boca Raton, FL, 2013; pp 9–65.

(15) Kondo, H.; Oritani, T.; Yamashita, K. *Agric. Biol. Chem.* **1990**, *54*, 1531.